Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

433
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
433
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

263
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
263
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The best words in the best order.

Nature·2011
Same author

Career decisions: Taking the plunge.

Nature·2011
Same author

Protein-protein interactions: Interactome under construction.

Nature·2010
Same author

Protein-protein interactions: Tools for the search.

Nature·2010
Same author

Protein-protein interactions: Real-time analysis.

Nature·2010
Same author

Biomedical science: Putting research into practice.

Nature·2010

関連する実験動画

Updated: May 6, 2026

Visualizing Visual Adaptation
04:43

Visualizing Visual Adaptation

Published on: April 24, 2017

8.6K

NIH助成のピアレビューの強化:より広い視点

Laura Bonetta

    Cell
    |October 30, 2008
    PubMed
    まとめ
    この要約は機械生成です。

    国立衛生研究所 (NIH) は,補助金の審査プロセスを更新しています. これらの変更により,NIHの手続きは欧州の資金調達モデルと整合し,独自の側面を保持します.

    さらに関連する動画

    Using Looming Visual Stimuli to Evaluate Mouse Vision
    05:07

    Using Looming Visual Stimuli to Evaluate Mouse Vision

    Published on: June 13, 2019

    11.1K
    Non-aversive Animal Restraint Enabling Recording of Optomotor Reflex in Ground Squirrels
    07:28

    Non-aversive Animal Restraint Enabling Recording of Optomotor Reflex in Ground Squirrels

    Published on: July 25, 2025

    1.9K

    関連する実験動画

    Last Updated: May 6, 2026

    Visualizing Visual Adaptation
    04:43

    Visualizing Visual Adaptation

    Published on: April 24, 2017

    8.6K
    Using Looming Visual Stimuli to Evaluate Mouse Vision
    05:07

    Using Looming Visual Stimuli to Evaluate Mouse Vision

    Published on: June 13, 2019

    11.1K
    Non-aversive Animal Restraint Enabling Recording of Optomotor Reflex in Ground Squirrels
    07:28

    Non-aversive Animal Restraint Enabling Recording of Optomotor Reflex in Ground Squirrels

    Published on: July 25, 2025

    1.9K

    科学分野:

    • 生物医学研究への資金提供
    • 補助金の管理 補助金の管理

    背景:

    • 国立衛生研究所 (NIH) は,重要な生物医学研究助成制度を管理しています.
    • 現在のNIH助成金申請審査プロセスは確立されていますが,改定中です.

    研究 の 目的:

    • ステークホルダーに,NIHの助成金審査プロセスの今後の変更について知らせる.
    • 助成金申請の評価に予定されている変更を強調する.

    主な方法:

    • NIHによる計画された手続き調整の分析.
    • 提案されたNIHの審査メカニズムと国際モデル,特に欧州の資金提供機関との比較.

    主要な成果:

    • NIHの助成金審査は,欧州の資金提供機関に似た要素を組み込む.
    • 改訂されたNIHシステムは,新しい適応とともに,独特の特徴を維持します.

    結論:

    • NIHは,補助金の審査システムを進化させ,効率と国際的調整を強化しています.
    • 利害関係者は,NIHの助成金申請の提出と審査の変更を今後数年間で準備する必要があります.